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Colorectal cancer is the second most common cause of cancer death in Britain and we are therefore looking for factors which might prevent or treat it. Lectins are plant proteins that bind to specific carbohydrate motifs. 1 They are abundant in the diet, 2 resist digestion, 3 4 remain active in the colon, 5 6 and notably aVect the function of gastrointestinal cells. 5 7 8 The group led by Rhodes showed that peanut lectin increases proliferation of the colonic mucosa and postulated that the binding of some lectins to genetically determined sugar motifs may stimulate the development of colorectal tumours. 9 The same group has recently shown that peanut ingestion increases rectal proliferation in individuals with mucosal expression of peanut lectin receptor Gal [1] [2] [3] Gal Nac− and suggests that this could be an important mechanism for the association between diet and colorectal cancer. 10 However, a high intake of vegetables, and therefore of lectins, actually decreases the likelihood of colorectal cancer. 11 Indeed some dietary lectins inhibit proliferation of colorectal carcinoma cell lines. 12 13 Although the proliferative eVects of dietary lectins on various colorectal carcinoma cell lines are well documented, 7 14 15 their eVects on diVerentiation of these cells are relatively unexplored. This is important because the loss of diVerentiation and invasion are the histological hallmarks of malignant cells. Therefore, we studied the eVects of a panel of dietary lectins which bind to diVerent sugar motifs on the diVerentiation, adhesion, and proliferation of human colon cancer cells. With regard to potential mechanisms, differentiation is regulated by cell adhesion molecules 16 which are glycosylated and are therefore potential targets for lectin binding. The possible role of adhesion molecules was investigated using a monoclonal antibody against epithelial cell adhesion molecule (epCAM), epithelial cadherin (E cadherin), and carcinoembryonic antigen (CEA). We report here that Vicia faba agglutinin (VFA), the lectin present in broad beans, which binds to mannose and glucose reverses the malignant phenotype of these cells, possibly through an interaction with epCAM. Confluent cells were detached with 2 mM EDTA, washed in DMEM, and suspended in DMEM/0.8% FCS. Cells (5 × 10 4 cells/ml) were allowed to aggregate for one hour at 37°C in the presence of lectins (10 µg/ml) on a gyratory shaker; remaining single cells were counted using a Coulter counter (Coulter Electronics, Inc.). Results were divided by the initial single cell count to give an aggregation index. In some studies haptenic sugars (50 mM) were added, in others monoclonal antibodies (50 µg/ml) were added to cells 30 minutes before initiating the assay, and in others DMEM was replaced with calcium free PBS. The extent of inhibition was expressed as percentage inhibition of the change in aggregation index produced by the lectin. WESTERN BLOTTING Cells were grown in the presence of PNA, SBA, ABL, WGA, and VFA (10 µg/ml) for 48 hours in 140 mm dishes. Cells were washed in ice cold phosphate buVered saline (PBS) containing the lectin specific haptenic sugars (5 mM) and scraped into 1 ml of sample buVer (2% sodium dodecyl sulphate (SDS), 10% glycerol, 5% 2-mercaptoethanol, 60 mM Tris-HCl, pH 6.8), and heat denatured for 10 minutes. Samples were clarified by centrifugation at 13 000 g for 10 minutes at 4°C, and the total protein concentration was quantified using the Bio-rad (Hertfordshire, UK) protein assay kit. Equal amounts of protein (30 µg) were then loaded and resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) on 8% polyacrylamide gel. Resolved proteins were transferred by electroblotting onto nitrocellulose membranes (Millipore, UK). Non-specific binding was blocked with 5% non-fat dried milk in TBS-T (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Tween 20) for two hours at room temperature, and then incubated overnight with AUA-1 antibody as neat supernatant. Membranes were incubated with horseradish peroxidase conjugated antimouse antibodies (0.5 mg/ml) (Dako, UK) for one hour at room temperature. After extensive washing, membranes were reacted for one minute with enhanced chemiluminescence reagent (ECL) (Amersham, UK) and exposed to hyperfilm-MP film (Amersham, UK).
Materials and methods

CELL PROLIFERATION
Harvested cells were plated into 96 well plates at an initial density of 2 × 10 4 cells/well in DMEM/10% FCS or 2% for ABL due to fetuin being present in the FCS. Cells were allowed to attach overnight and were then incubated for 24 hours in fresh serum free medium. Complete medium contained lectin to a final concentration of 1, 10, or 100 µg/ml.
In competition studies the eVects of the specific haptenic sugar (50 mM)-SBA (Nacetylgalactosamine), PNA (galactose); ABL (fetuin), WGA (N,Ní,Níí-triacetylchitotriose), and VFA (mannose)-for each lectin was tested in the presence and absence of the lectin. All sugars were added to the wells prior to the addition of lectin. After incubating for a further 48 hours, 3 H thymidine (2 µCi/well) was added for a further eight hours. Cells were then washed three times with distilled water, and lysed with 200 µl of 1 M KOH for one hour at 37°C. Samples (50 µl) from each well were then mixed with scintillation fluid (1 ml) (Optiphase safe, LKB, Leicester, UK) and counted in a beta scintillation counter (Beckman Instruments, Inc., California, USA) for one minute per sample.
AMINO ACID INCORPORATION
The protocol was the same as above, except that 1 mCi DiVerentiation was studied by culture in three dimensional collagen gels. Briefly, single cell suspensions (2 × 10 4 /ml) in DMEM with vitrogen 100 (Imperial Laboratories, UK) were allowed to gel for one hour, then DMEM with or without 2% FCS was added to the gels for 24 hours. Lectins were added in duplicate at 1, 10, and 100 µg/ml with or without 50 mM of their haptenic sugars and replaced every four days for 21 days. Monoclonal antibodies HECD1, PR3B10, and AUA-1 were added in serial dilutions throughout the experiment. Purified mouse immunoglobulins (50 µg/ml) acted as control. Plates were examined daily by phase contrast microscopy to detect glandular structures, defined as organised cell aggregates with central lumen composed of epithelial cells having nuclei polarised towards the basal surface of the cell. Formalin fixed gels were stained with haematoxylin and eosin and alcian blue-periodic acid SchiV (PAS), and photographed.
STATISTICAL ANALYSIS
Student's t test was used to analyse cell-cell adhesion. Unpaired two sample t tests were used for proliferation studies. If a significant diVerence was observed between the variances, data were then analysed by the Mann-Whitney test. A result was considered significant when p<0.05. Figure 1 shows the eVects of lectins on cell-cell adhesion.
Results
MODULATION OF CELL-CELL ADHESION BY
LECTINS
LS174T cells-Significant aggregation of LS174T cells occurred following incubation with VFA, WGA, and ABL (10 µg/ml) (p<0.01). Cell-cell adhesion was promoted weakly by PNA and SBA, although the eVect was not statistically significant.
HT29 cells-All lectins (10 µg/ml) significantly aggregated HT29 cells compared with control over one hour (p<0.01).
SW1222 cells-PNA, SBA, ABL, VFA, and WGA (10 µg/ml) significantly aggregated the cells compared with control over one hour (p<0.01).
Aggregation of all three cell types by lectins was completely blocked by their specific haptenic sugars (50 mM) (data not shown). In addition the response to the lectins did not occur in calcium free medium (data not shown). There was no diVerence in aggregation by any lectin either in the absence or presence of FCS. Aggregation of LS174T cells by VFA was significantly blocked by monoclonal antiepCAM antibody, AUA-1 (p<0.05). However, antibodies against anti-E cadherin (HECD-1) and anti-CEA (PR3B10) did not block cell aggregation induced by VFA or any other lectin tested.
EFFECT OF LECTINS ON THE STEADY STATE EXPRESSION OF epCAM
None of the lectins tested had any significant eVect on the expression of epCAM in LS174T cells. Immunoblotting detected bands of (46 kDa) of almost equal intensities in both unstimulated and lectin stimulated cells. The blot (fig 2) represents one of three experiments which all gave similar results. Figure 3 shows the eVect of lectins on proliferation.
EFFECT OF LECTINS ON PROLIFERATION
LS174T cells-PNA and SBA (1, 10, and 100 µg/ml) produced a slight increase in thymidine incorporation into LS174T cells. By contrast, VFA and ABL (1, 10, and 100 µg/ml) dose dependently inhibited proliferation of LS174T cells (p<0.05). WGA (1, 10, and 100 µg/ml) significantly inhibited thymidine incorporation (p<0.05) but was cytotoxic at 100 µg/ml. A lack of cytotoxicity of lectins was also demonstrated by amino acid incorporation. Only VFA (1, 10, 100 µg/ml) dose dependently increased amino acid incorporation in LS174T cells.
HT29 cells-VFA and ABL (1, 10, and 100 µg/ml) dose dependently inhibited proliferation (p<0.05). Neither lectin was cytotoxic following trypan blue exclusion; although WGA was inhibitory at low concentrations (p<0.05) it was cytotoxic at 100 µg/ml following trypan blue exclusion. In contrast PNA (1, 10, and 100 µg/ml) dose dependently stimulated proliferation of HT29 cells (p<0.05). SBA had no significant eVect at any concentration. SW1222 cells-VFA and ABL (1, 10, and 100 µg/ml) dose dependently inhibited proliferation of SW1222 cells (p<0.05). WGA (1 and 10 µg/ml) significantly inhibited proliferation (p<0.05), and was cytotoxic to the cells at 100 µg/ml following trypan blue exclusion. PNA (10 and 100 µg/ml) significantly stimulated proliferation (p<0.05) but SBA had no significant eVect at any concentration.
In competition studies the eVects of lectins on proliferation of all the cell lines were blocked by their specific haptenic sugars (50 mM). However, mannose did not reverse the antiproliferative eVect of VFA but inhibited proliferation when given alone (data not shown).
EFFECT OF LECTINS ON GLANDULAR
DIFFERENTIATION
When grown for two weeks in collagen, LS174T cells formed single disorganised groups of cells and did not show any pattern of glandular diVerentiation in the presence or absence of FCS ( fig 4A) . However, when grown in the presence of VFA (1, 10, and 100 µg/ml) with or without FCS, cells showed a tendency to form organised glandular structures consisting of a single layer of cells with basally arranged nuclei around a central lumen containing mucin (fig 4B) . This eVect was inhibited in the presence of the anti epCAM monoclonal antibody AUA-1 (50 µg/ml) and mannose (not shown). None of the other lectins tested had any significant eVect on diVerentiation of this cell line. There was no significant eVect on diVerentiation in SW1222 or HT29 cells when incubated with lectins.
Discussion
We have shown for the first time that VFA, the lectin present in broad beans, can increase morphological diVerentiation and thus diminish the malignant phenotype of colorectal cancer cells. Cell aggregation is necessary for normal colonocyte diVerentiation 19 but in the present study some lectins also caused aggregation without inducing diVerentiation. The eVect of VFA on cell-cell adhesion of LS174T cells was blocked by monoclonal antibody AUA-1 against epCAM but not by monoclonal antibodies against CEA or E cadherin; this suggests a specific eVect on epCAM. No lectin had any significant eVect on the expression of epCAM which suggests that VFA acts either by binding directly to epCAM, which is N-glycosylated, 20 21 or through a pathway which involves epCAM. It remains to be seen whether VFA binds directly to epCAM.
It is possible that lectins interact with cell surface adhesion molecules in a ligandreceptor fashion, which leads to activation of a signalling pathway. This is supported by the evidence that adhesion molecules participate in a large variety of signal transduction events important for regulating not only cell adhesion but also migration, growth, apoptosis, and specific gene regulation. 22 It is also possible that VFA may act on a specific cell-surface receptor. In competition studies mannose did not block the eVect of VFA on proliferation but when given alone, also dose dependently inhibited proliferation. Growth factor receptors (EGFR) are often glycosylated, and lectins have been shown to bind to them. 23 Mannose residues are present on the EGFR 24 and several mannose binding lectins have been shown to inhibit binding of epidermal growth factor (EGF) to its receptor. 25 Therefore, mannose may have blocked the eVect of endogenous EGF in the medium of the cell lines tested. We have shown previously that transforming growth factor , which is a physiological ligand for the EGF receptor, had a similar eVect to VFA on a diVerent colonic epithelial cell line. 26 Therefore, VFA may mimic the eVects of growth factors.
The diVerence in the cellular response of colorectal carcinoma cell lines to diVerent lectins is consistent with other studies and may reflect diVerences in the number of lectin binding sites on diVerent colonic cell lines. 5 WGA binds specifically to sialic acid and GlcNAc and also significantly aggregated the LS174T cells but this was not blocked by monoclonal antibody AUA-1. Although ABL and PNA both bind to Gal 1-3 Gal Nac−, only ABL had a significant eVect on aggregation of LS174T cells. The diVerence may reflect the ability of ABL to bind to sialyated Gal 1-3 Gal Nac. 12 Therefore, binding sites for PNA may have been masked by sialyation. SBA binds to N-acetyl-D-galactosamine and D-galactose; therefore the diVerences in cell adhesiveness to SBA may reflect the presence or absence of these motifs in these cells.
VFA and ABL dose dependently inhibited proliferation of all cell lines, an eVect that was reversible and not associated with cytotoxicity. VFA has previously been shown to inhibit proliferation of Caco-2 cells, 13 but ABL had no eVect on these cells. 5 Whether this reflects available binding sites for these lectins or diVerences in their mode of action is still unclear. However, their lack of cytotoxicity suggests a diVerent mechanism of action to that observed with other lectins. Lectin binding epitopes, while essential, are not suYcient for tumour cell lysis because some lectins bind but have no eVects. Studies have shown that some lectins are internalised by cells 27 and trigger apoptosis. 28 ABL has also been shown to inhibit proliferation of HT29 cells following internalisation. 29 Other potential lectin binding sites include glycosylated regions of cell surface adhesion molecules. For example CD44 is the major peanut lectin binding glycoprotein on human epidermal keratinocytes. 30 WGA binds to the core of CEA whereas concanavalin A (Con A), another mannose/glucose specific lectin, binds to peripheral residues. 31 WGA also aggregates membrane vesicles through an interaction with the neural cell adhesion molecule (NCAM). 32 With regard to potential therapeutic eVects, VFA is fairly resistant to digestion 3 4 and was not cytotoxic when fed to animals. 33 Therefore, VFA appears to be the only known non-toxic dietary lectin other than ABL with inhibitory eVects on proliferation. Although there are a limited number of sites for binding of mannose binding lectins in the gastrointestinal tract they have been identified in the proximal but not the distal colon. 34 However, many more cell surface proteins are N-glycosylated and likely to contain some mannose, so the lack of binding of mannose binding lectins is likely to reflect diVerences in lectin aYnity rather than the simple presence or absence of mannose. VFA and other mannose binding plant lectins may contribute to protection from colorectal cancer by vegetables through eVects on tumour development. In addition the new data implicating epCAM in the eVect suggests a new target through which the behaviour of tumours might be modified. We are currently investigating the eVects of VFA and other plant and mammalian mannose binding lectins on the development of gastrointestinal tumours.
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